RxDoctor Payments Data

Ashley Blackburn

Family Medicine · Reading, PANPI 1427822378

Payments from drug & device makers

$3,330in general payments, 2019–2025

Across 157 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$660
  • AbbVie$507
  • AstraZeneca$462
  • Lilly USA, LLC$314
  • Pfizer$291
  • Amgen$177
  • plus $919 from 17 others

What the payments were for

  • Food & beverage$3,330100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,330 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,802
Medicare patients
346
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$29,451
OzempicSemaglutide20$18,025
EliquisApixaban11$11,757
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$1,117
Duloxetine Hcl31$790
Fluticasone Propionate64$687
Tramadol Hcl53$615
Valsartan25$554
Atorvastatin Calcium59$512
Albuterol Sulfate HfaAlbuterol Sulfate16$472
Metoprolol Succinate39$427
Ezetimibe11$421
Rosuvastatin Calcium32$406
Gabapentin35$371
Bupropion XlBupropion Hcl15$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$314$29,45128 claims
Novo NordiskOzempic$660$18,02520 claims
PfizerEliquis$291$11,75711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →